Phoebe Starr

Authored Items
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
JHOP Web Exclusives in Leukemia
Paradigm Shift: Ibrutinib plus Rituximab Front-Line Therapy for Patients with CLL Under Age 70
Phoebe Starr
JHOP Web Exclusives in Leukemia
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 in Breast Cancer, Immunotherapy
5-mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
JHOP Web Exclusives in Breast Cancer
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Leukemia
Selective RET Inhibitor, BLU-667, Hits the Target in Patients with Lung or Thyroid Cancers
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Emerging Therapies
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Emerging Therapies
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Breast Cancer
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
Phoebe Starr
TON - September 2018, Vol 11, No 4 in Prostate Cancer
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation
Phoebe Starr
JHOP Web Exclusives in Emerging Therapies
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
JHOP Web Exclusives in Immunotherapy
A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - August 2018, Vol 11, No 2 in Lung Cancer
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
TOP - August 2018, Vol 11, No 2 in Immunotherapy
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 in Breast Cancer
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TON - July 2018, Vol 11, No 3 in Breast Cancer
Apalutamide and Enzalutamide Each Delays Prostate Cancer Metastasis by Approximately 2 Years
Phoebe Starr
TOP - May 2018, Vol 11, No 1 in Prostate Cancer
Adjuvant Chemotherapy in Upper-Tract Urothelial Cancer Shows Impressive Gains in the POUT Trial
Phoebe Starr
TOP - May 2018, Vol 11, No 1 in Genitourinary Cancers
Immune Checkpoint Inhibitor plus VEGFR Inhibitor Combo Outperforms Sunitinib in Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2018, Vol 11, No 1 in Renal-Cell Carcinoma
Venetoclax plus Rituximab New Chemotherapy-Free Option for Chronic Lymphocytic Leukemia
Phoebe Starr
TOP Web Exclusives in Leukemia
A New Combination as First-Line Regimen in Advanced Hodgkin Lymphoma?
Phoebe Starr
TOP Web Exclusives in Lymphoma
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 in Conference Correspondent
Psychological Distress in Patients with Cancer Warrants Attention
Phoebe Starr
TON - November 2017, Vol 10, No 6 in Conference Correspondent
Patients’ Chemotherapy-Related Side-Effect Concerns Have Evolved, But Hair Loss Remains Significant
Phoebe Starr
TON - November 2017, Vol 10, No 6 in Conference Correspondent
Increased Cancer Risk in Postmenopausal Women with Central Obesity
Phoebe Starr
TON - November 2017, Vol 10, No 6 in Conference Correspondent
Patients’ Fears of Radiation Side Effects Largely Unfounded
Phoebe Starr
TON - November 2017, Vol 10, No 6 in Conference Correspondent
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Lung Cancer
Pembrolizumab Makes Inroads in Sarcoma Subtypes
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Immunotherapy, Online First
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Breast Cancer
Novel Drug “Home Run” for TRK Mutation–Positive Tumors
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Emerging Therapies
Healthy Lifestyle Improves Survival in Patients with Colon Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 in Colorectal Cancer, Conference Correspondent
8-Week Internet-Based Psychological Intervention Reduces Stress in Patients Newly Diagnosed with Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 in Conference Correspondent
More Support for Regular Use of Low-Dose Aspirin
Phoebe Starr
TON - September 2017, Vol 10, No 5 in Conference Correspondent
Cardiotoxicity with Targeted Therapies Is Rare, but Requires Attention
Phoebe Starr
TON - September 2017, Vol 10, No 5 in Conference Correspondent
Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in Melanoma, Immunotherapy
Enzalutamide Safe for Patients at Increased Risk for Seizure
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in Prostate Cancer
Nivolumab/Ipilimumab Combination Extends Survival for Patients with Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in Melanoma, AACR News, Conference Correspondent
Pursuit of Biomarkers for CDK4/CDK6 Response Fails
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in AACR News, Conference Correspondent
Abemaciclib Moves Forward in Metastatic Breast Cancer
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in AACR News, Conference Correspondent
Survivorship Care Evolves with Fine-Tuning
Phoebe Starr
TON - July 2017, Vol 10, No 4 in Survivorship
Reasons for Emergency Department Visits Related to Immune Checkpoint Inhibitor Treatment
Phoebe Starr
TON - July 2017, Vol 10, No 4 in Adverse Effects
Hormonal Therapy Associated with Anxiety in Men with Localized Prostate Cancer
Phoebe Starr
TON - May 2017, Vol 10, No 3 in Genitourinary Cancers
New NCCN Distress Guidelines and Tools Encourage Patients to Speak Up
Phoebe Starr
TON - May 2017, Vol 10, No 3 in Conference Correspondent, NCCN News
Discontinuing Immunotherapy Because of Adverse Effects May Not Compromise Efficacy
Phoebe Starr
TON - May 2017, Vol 10, No 3 in Adverse Effects
Toxicities of Immunotherapy Require Awareness, Education
Phoebe Starr
TON - May 2017, Vol 10, No 3 in Adverse Effects
Discontinuing Immunotherapy Because of Adverse Effects May Not Compromise Efficacy
Phoebe Starr
TOP - May 2017, Vol 10, No 2 in Adverse Effects
Reasons for Emergency Department Visits Related to Immune Checkpoint Inhibitor Treatment
Phoebe Starr
TOP - May 2017, Vol 10, No 2 in Adverse Effects
Autologous Breast Reconstruction Has Better Outcomes Than Implants in Patients Receiving Radiotherapy
Phoebe Starr
TON - March 2017, Vol 10, No 2 in Breast Cancer
Specific Menopausal Symptoms Associated with Nonadherence to Hormonal Therapy in Women at Risk for Breast Cancer
Phoebe Starr
TON - March 2017, Vol 10, No 2 in Breast Cancer
Obinutuzumab Prolongs Survival in Follicular Lymphoma
Phoebe Starr
JHOP Web Exclusives in Conference Correspondent, ASH 2016 - Roundup
CAR T-Cell Therapy Succeeds in Aggressive Lymphoma
Phoebe Starr
JHOP Web Exclusives in Conference Correspondent, ASH 2016 - Roundup
R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
Phoebe Starr
In the News: Oncology - February 2017 in Conference Correspondent
Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Phoebe Starr
In the News: Oncology - February 2017 in Conference Correspondent
Duloxetine Helps Reduce Aromatase Inhibitor–Associated Joint Pain
Phoebe Starr
TOP - February 2017, Vol 10, No 1 in Breast Cancer
Increased Attention to Cardiovascular Events in DLBCL Warranted
Phoebe Starr
TON - January 2017, Vol 10, No 1 in Conference Correspondent
Use Caution When Placing Catheters in Children with Cancer
Phoebe Starr
TON - January 2017, Vol 10, No 1 in Conference Correspondent
Call to Action: Address Patients’ Sexual Health
Phoebe Starr
TON - November 2016, Vol 9, No 6 in Supportive Care
Older Drugs in “New Clothes” Achieve Superior Outcomes
Phoebe Starr
TON - November 2016, Vol 9, No 6 in Hematologic Cancers
Older Drugs in “New Clothes” Achieve Superior Outcomes
Phoebe Starr
TOP - November 2016, Vol 9, No 4 in Hematologic Cancers
Aggressive End-of-Life Care Continues to Be Offered to Younger Patients with Cancer
Phoebe Starr
TON - September 2016, Vol 9, No 5 in Best Practices, Palliative Care
Price of Drugs and Affordability Don’t Always Jibe
Phoebe Starr
TOP - August 2016, Vol 9, No 3 in Conference Correspondent
Reassuring Practice Patterns in the Use of Curative Treatment for Men with Prostate Cancer
Phoebe Starr
TOP - May 2016, Vol 9, No 2 in Genitourinary Cancers
Aspirin Reduces Risk for Prostate Cancer Death
Phoebe Starr
TON March 2016 Vol 9 No 2 in Genitourinary Cancers
Docetaxel Does Not Compromise Long-Term QOL in Men with Metastatic Hormone-Sensitive Prostate Cancer
Phoebe Starr
TON March 2016 Vol 9 No 2 in Genitourinary Cancers
Active Holistic Surveillance Incorporates Diet, Supplements, Exercise for Low-Risk and Low-Intermediate–Risk Prostate Cancer
Phoebe Starr
TON March 2016 Vol 9 No 2 in Genitourinary Cancers
ABCs of Immunotherapy
Phoebe Starr
TOP November 2015 Vol 8 No 4 in Immunotherapy
Chemotherapy, Radiation Safe During Pregnancy in Second or Third Trimester
Phoebe Starr
TON November 2015 Vol 8 No 6 in Supportive Care
ABCs of Immunotherapy
Phoebe Starr
TON September 2015 Vol 8 No 5 in Online First
The State of Antibody-Drug Conjugates in 2015
Phoebe Starr
TON September 2015 Vol 8 No 5 in Drug Therapies
Being Single Raises Risks of Death for Patients with Cancer
Phoebe Starr
TON July 2015 Vol 8 No 4 in Supportive Care
No Role for Adjuvant Sorafenib or Sunitinib in Locally Advanced Kidney Cancer
Phoebe Starr
TON May 2015 Vol 8 No 3 in Genitourinary Cancers
AR-V7 Predicts Chemotherapy Sensitivity in Metastatic Prostate Cancer
Phoebe Starr
TON May 2015 Vol 8 No 3 in Genitourinary Cancers
ASSURE Trial: No Role for Adjuvant Sorafenib or Sunitinib in Locally Advanced Kidney Cancer
Phoebe Starr
TOP - May 2015, Vol 8, No 2 in Genitourinary Cancers
Venetoclax Moves Forward in Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
Phoebe Starr
TOP - February 2015, Vol 8, No 1 in Hematologic Cancers
Novel Agent Effective for the Management of Cancer-Related Cachexia
Phoebe Starr
TOP - February 2015, Vol 8, No 1 in Supportive Care
Posttransplant Brentuximab: New Standard of Care for Hodgkin Lymphoma?
Phoebe Starr
TOP - February 2015, Vol 8, No 1 in Hematologic Cancers
Novel Agent Effective for the Management of Cancer-Related Cachexia
Phoebe Starr
TON - January 2015 Vol 8 No 1 in Supportive Care
Potential New Approach to Treat Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 in Skin Cancer
Combination of BRAF and MEK Inhibitors Improves Survival in Advanced Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 in Skin Cancer
Angiotensin System Inhibitors Extend Survival in Patients With Metastatic Renal Cell Carcinoma
Phoebe Starr
TOP - May 2014, Vol 7, No 2 in Genitourinary Cancers
Enzalutamide Extends Survival in Previously Untreated Metastatic Prostate Cancer
Phoebe Starr
TOP - May 2014, Vol 7, No 2 in Genitourinary Cancers
Role of Radiation and Imaging in DCIS Explained
Phoebe Starr
TON - January/February 2014 Vol 7 No 1 in Breast Cancer
Pazopanib: First Positive Maintenance Trial
Phoebe Starr
TON - December 2013 Vol 6 No 11 in Gynecologic Cancers
Two-Thirds of Women Experience Musculoskeletal Toxicity on Aromatase Inhibitors and 22.9% Discontinue Therapy
Phoebe Starr
TOP - May 2013, Vol 6, No 2 in Breast Cancer
Two-Thirds of Women Experience Musculoskeletal Toxicity on Aromatase Inhibitors and 22.9% Discontinue Therapy
Phoebe Starr
TON - March 2013, Vol 6, No 2 in Breast Cancer
Proton Beam Therapy: Similar Toxicity to Standard Radiation, at Much Higher Cost
Phoebe Starr
TOP - December 2012 VOL 5, NO 8 in Genitourinary Cancers
Last modified: December 21, 2012